Homocysteine impairs estrogen-induced vasodilation in isolated rat arterioles

Menopause

Volumn 11, Issue 1, 2004, Pages 98-103

  Smolders, Raimond G V ^a,b   Sipkema, Pieter ^b   Kenemans, Peter ^a,b   Stehouwer, Coen D A ^b   Van Der Mooren, Marius J ^a,b  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Animal; Estradiol; Homocysteine; Spontaneous constriction; Vasodilation

Indexed keywords

ESTRADIOL; ESTROGEN; HOMOCYSTEINE; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; ENZYME INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTERY MUSCLE; ARTICLE; BLOOD VESSEL REACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; ENDOTHELIUM CELL; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FEMALE; GRACILIS MUSCLE; HEART PROTECTION; INHIBITION KINETICS; METABOLIC REGULATION; NONHUMAN; PATHOPHYSIOLOGY; RAT; VASODILATATION; ANIMAL; BLOOD; DRUG EFFECT; METABOLISM; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; WISTAR RAT;

ANIMALS; ARTERIOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ESTRADIOL; FEMALE; HOMOCYSTEINE; MUSCLE, SMOOTH, VASCULAR; NITROARGININE; RATS; RATS, WISTAR; VASOCONSTRICTION; VASODILATION;

EID: 2442692003     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GME.0000079220.19081.58     Document Type: Article

References (25)

1. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med 1993;329:247-256.
2. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057.
3. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775-1781.
4. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993;91:2873-2879.
5. Upchurch GR Jr, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997;272:17012-17017.
6. Raghuveer G, Sinkey CA, Chenard C, Stumbo P, Haynes WG. Effect of vitamin E on resistance vessel endothelial dysfunction induced by methionine. Am J Cardiol 2001;88:285-290.
7. Weiss N, Zhang YY, Heydrick S, Bierl C, Loscalzo J. Overexpression of cellular glutathione peroxidase rescues homocyst(e)ine-induced endothelial dysfunction. Proc Natl Acad Sci VSA 2001;98:12503-12508.
8. Weiss N, Heydrick S, Zhang YY, Bierl C, Cap A, Loscalzo J. Cellular redox state and endothelial dysfunction in mildly hyperhomocysteinemic cystathionine beta-synthase-deficient mice. Arterioscler Thromb Vasc Biol 2002;22:34-41.
9. Tyagi SC, Smiley LM, Mujumdar versus Homocyst(e)ine impairs endocardial endothelial function. Can J Physiol Pharmacol 1999; 77:950-957.
10. Ungvari Z, Pacher P, Rischak K, Szollar L, Koller A. Dysfunction of nitric oxide mediation in isolated rat arterioles with methionine diet-induced hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 1999;19:1899-1904.
11. Simoncini T, Genazzani AR. Direct vascular effects of estrogens and selective estrogen receptor modulators. Curr Opin Obstet Gynecol 2000;12:181-187.
12. Smolders RGV, van der Mooren MJ, Kenemans P, van der Linden PWJ, Stehouwer CDA, Sipkema P. 17β-estradiol induces a rapid, endothelium-dependent, sex-specific, vasodilatation in spontaneous constricted rat arterioles. Am J Obstet Gynecol 2002;187:375-381.
13. Freedman JE, Frei B, Welch GN, Loscalzo J. Glutathione peroxidase potentiates the inhibition of platelet function by S-nitrosothiols. J Clin Invest 1995;96:394-400.
14. Hultberg B, Andersson A, Isaksson A. Hypomethylation as a cause of homocysteine-induced cell damage in human cell lines. Toxicology 2000;147:69-75.
15. Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 1998;351: 36-37.
16. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987;262:10098-10103.
17. Okatani Y, Wakatsuki A, Reiter RJ. Melatonin counteracts potentiation by homocysteine of KCL-induced vasoconstriction in human umbilical artery: relation to calcium influx. Biochem Biophys Res Commun 2001;280:940-944.
18. Stefano GB, Prevot V, Beauvillain JC et al. Cell-surface estrogen receptors mediate calcium-dependent nitric oxide release in human endothelia. Circulation 2000;101:1594-1597.
19. Huang A, Sun D, Koller A, Kaley G. Gender difference in myogenic tone of rat arterioles is due to estrogen-induced, enhanced release of NO. Am J Physiol 1997;272:H1804-H1809.
20. Van der Mooren MJ, Wouters MG, Blom HJ, Schellekens LA, Eskes TK, Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994;24:733-736.
21. Mijatovic V, Kenemans P, Netelenbos C, et al. Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. Fertil Steril 1998;69:876-882.
22. Van Baal WM, Smolders RGV, van der Mooren MJ, Teerlink T, Kenemans P. Hormone replacement therapy and plasma homocysteine levels. Obstet Gynecol 1999;94:485-491.
23. Hak AE, Bak AA, Lindemans J, et al. The effect of hormone replacement therapy on serum homocysteine levels in perimenopausal women: a randomized controlled trial. Atherosclerosis 2001; 158:437-443.
24. Smolders RGV, Vogelvang TE, Mijatovic V, et al. A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine. Maturitas 2002;41: 105-114.
25. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-613.